Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer
Status:
Not yet recruiting
Trial end date:
2030-07-31
Target enrollment:
Participant gender:
Summary
This phase II/III trial studies how well neoadjuvant short-course radiotherapy and
chemotherapy with or without PD-1 inhibitors works in treating patients with locally advanced
rectal adenocarcinoma. Neoadjuvant short-course radiation therapy followed by two-drug
regimen chemotherapy, such as CAPOX, were shown to be non-inferior to standard long-course
chemoradiotherapy in our previous STELLAR study. Immune checkpoint inhibitors (ICIs) using
monoclonal antibodies, such as PD-1 or PD-L1 inhibitor, show promising efficiency and
reliable security in some limited sample prospective or retrospective studies. When treating
patients with locally advanced rectal cancer, giving sequential neoadjuvant short-course
radiotherapy and chemotherapy with PD-1 inhibitor may work better.